POTENTIAL DEAL DETAILS
|Date Announced||02/26/2023||Source||Wall Street Journal|
|Date of Confirmation:||03/13/2023||Price at Confirmation:||N/A|
|Potential Profit:||10.93%||Annualized Profit:||142.53%|
According to WSJ, Pfizer (PFE) is in talks to acquire biotech Seagen (SGEN) in a deal likely valued at more than $30 billion.
Previously on June 2022, Merck & Co (MRK) considered buying cancer-focused biotech company Seagen (SGEN) but the two sides failed to reach an agreement.
March 13, 2023: Pfizer (PFE) has agreed to pay $43 billion for biotech Seagen (SGEN)and its pioneering class of targeted cancer drugs.
Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.